Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

A Phase 1b, Open-Label Study of the Safety and Efficacy of Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor (DAR)-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05007418
• Other study ID #: 38DART-RRMM-101
• Status: Recruiting
• Phase: Phase 1
• Start date: October 1, 2022
• Est. completion date: February 2026

Study information

• Verified date: January 2023
• Source: Sorrento Therapeutics, Inc.
• Contact: Mike Royal, MD
• Phone: (858)203-4100
• Email: mroyal[@]sorrentotherapeutics.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.

Description:

This is a phase 1b, open-label, multicenter, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma. The study will determine the MTD and RP2D, assessing safety and preliminary efficacy using a conventional 3+3 study design with two design stages, an ascending dose stage followed by an expansion study. Patients will be enrolled sequentially within each cohort and between cohorts during the dose escalation portion of the study with the staggered intervals of at least 28 days. Only one patient will be allowed to receive study treatment at any time through the end of the staggering period before the next subject may begin study treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 54
• Est. completion date: February 2026
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Must have relapsed or refractory multiple myeloma (RRMM) after having received prior lines of anti-myeloma treatments.
• Measurable disease as defined by one of the following: abnormal serum or M-protein levels; abnormal serum free light chain (FLC) assay; = 30% clonal plasma cells in the bone marrow aspirate or biopsy sample
• Evidence of cell membrane CD38 expression as determined by immunohistochemistry (IHC) analysis ofbone marrow biopsy or extramedullary plasmacytoma
• Pulse oximetry = 92% on room air
• Have a life expectancy = 12 weeks
• Be willing and able to comply with the study schedule and all study requirements
• Willing to follow contraception guidelines

Exclusion Criteria:

• Previous treatment with any systemic therapy for multiple myeloma within 14 days prior to start of study dose
• Treatment with any cellular therapy within 8 weeks prior to start of study dose
• Have any unresolved toxicity = Grade 2 from previous anticancer therapies
• A history of brain metastasis or spinal cord compression
• Has an ECOG performance status (PS) = 3
• Has received allogeneic hematopoietic stem cell transplantation (HSCT) within 6 months, has active graft-versus-host disease (GvHD) following transplant, or is currently receiving immunosuppressive therapy following transplant
• Has any clinically significant low baseline lab results for hemoglobin, platelet counts, and neutrophil counts at screening unless resulting from underlying RRMM
• Has any clinically significant elevated baseline lab results for serum creatinine, AST or ß2 microglobulin
• Abnormal INR or aPTT, unless on a stable dose of an anticoagulant
• Has known HIV or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or C
• Is currently pregnant or breast feeding or planning on either during the study.
• Has an active bacterial, viral, or fungal infection
• Has active plasma cell leukemia
• Has extramedullary plasmacytoma(s)
• Has any significant medical condition, abnormality, or psychiatric illness that would prevent study participation
• Has left ventricular ejection fraction (LVEF) < 40%
• Has second primary malignancies (SPMs) in addition to multiple myeloma if the SPM has required therapy within the last 3 years or is not in complete remission
• Has any additional clinical history of the CNS or cardiovascular disease that would place the patient at an unacceptable risk if the patient participates in the study

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Biological:
• STI-1492
Anti-CD38 A2 KOKI DAR T cells

Locations

Country	Name	City	State
United States	University of Oklahoma	Oklahoma City	Oklahoma
United States	UC Irvine	Orange	California
United States	UC Davis	Sacramento	California

Sponsors (1)

Lead Sponsor	Collaborator
Sorrento Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of STI-1492	Safety as assessed by incidence of adverse events, SAEs, DLTs, neurotoxicity, cytokine release syndrome, host rejection, and laboratory abnormalities	Baseline through study completion at up to approximately 54 months
Secondary	Overall response and duration	Response and duration according to the International Myeloma Working Group (IMWG) response criteria	Baseline through study completion at up to approximately 54 months
Secondary	Assessment of improvements in hypercalcemia, renal function, anemia and lytic bone lesions (CRAB criteria)	Assessment of improvement in CRAB criteria	Baseline through study completion at up to approximately 54 months
Secondary	Assessment of serum immunoglobulin levels	Assessment of serum immunoglobulin levels	Baseline through study completion at up to approximately 54 months